Status: Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Participants needed: 677
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Aug 20, 2026Locations: 82
Eligibility criteria
Cohort A1, C1, D1, and D2: Locally advanced or metastatic solid tumor malignancy... [+11]
Participants with primary central nervous system (CNS) malignancy. [+23]